HDV: Dividends In Fashion To Kick Off 2026 (Rating Upgrade)
The iShares Core High Dividend ETF is upgraded to buy, as valuation improves and technicals signal further upside. HDV offers a 3.0% yield, low 0.08% expense ratio, and strong exposure to quality US large-cap value stocks. Sector overweights in Consumer Staples (27.5%) and Energy (25%) drive recent outperformance and January alpha.
What Retirees Need To Know About HDV's Dividend Before Buying
The iShares Core High Dividend ETF ( NYSEARCA:HDV ) offers retirees a 3.3% yield with 0.08% fees, tracking high-quality U.S.
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
If you're interested in broad exposure to the Large Cap Value segment of the US equity market, look no further than the iShares Core High Dividend ETF (HDV), a passively managed exchange traded fund launched on March 29, 2011.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
A smart beta exchange traded fund, the iShares Core High Dividend ETF (HDV) debuted on 03/29/2011, and offers broad exposure to the Style Box - Large Cap Value category of the market.
HDV: A Defensive Dividend Play
The iShares Core High Dividend ETF offers a quality-biased, low-beta portfolio focused on large-cap, defensive sectors like consumer staples, healthcare, and energy. HDV provides an attractive 3.2% dividend yield and trades at a discount to the broader market but at a premium compared to most dividend ETF peers. The fund's defensive sector tilt and low volatility profile limit downside risk, yet result in underperformance during bull markets and high exposure to oil prices.
2 High-Yielding ETFs That You Can Rely on for Recurring Income
Generating recurring income for your portfolio can be a great way to grow its value and provide you with a way to generate cash flow without having to sell stocks. You can then use that money to pay bills, pad your savings, or even have it reinvested back into stocks.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
The iShares Core High Dividend ETF (HDV) made its debut on 03/29/2011, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Value category of the market.
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
The iShares Core High Dividend ETF (HDV) was launched on 03/29/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
HDV: Nice Rally, Now Sell This Dividend Weakling
HDV's 3.45% dividend yield is underwhelming given the mediocre quality of its current portfolio holdings. Despite a recent market-wide pop, HDV offers no meaningful alpha and remains a 'dead money' situation in my view. Compared to SPY and even RSP, HDV consistently underperforms, only occasionally outpacing RSP when its own returns are weak.
HDV: This Core High Dividend ETF Is Back On My Watchlist
iShares Core High Dividend ETF comprises 75 high-quality U.S. securities that pay above-average dividend yields and pass Morningstar's Economic Moat, Uncertainty, and Distance to Default screens. Its long-term track record is mixed, but the fund has a low portfolio beta and has demonstrated solid safety in market drawdowns. Consumer Staples exposure is now at 22%. I estimate the fund yields 3.48% at current prices. HDV also features decent mid-single-digit sales and earnings growth rates, something not offered by higher-yielding funds, including SCHD.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
Making its debut on 03/29/2011, smart beta exchange traded fund iShares Core High Dividend ETF (HDV) provides investors broad exposure to the Style Box - Large Cap Value category of the market.
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
Vir Biotechnology, Inc.'s phase 3 ECLIPSE program for HDV, leveraging tobevibart and elebsiran, shows promise based on positive phase 2 SOLSTICE study results. The global hepatitis D market size is projected to surpass $1.05 billion by 2034. VIR-5518 and VIR-5500 are dual-masked HER2 and PSMA T-cell engagers being developed to target solid tumors; The current status of these candidates is that dose-escalation for both are ongoing.
